Lung cancer among postmenopausal women treated with estrogen alone in the womens health initiative randomized trial
Yu Y, Song J, Guo X, Wang S, Yang X, Chen L et al
Concerns include reports of adverse events, some requiring hospitalization, that may be related to dosing errors or doses beyond what is in the FDA-approved drug label, which means using more product in a single dose, taking doses more frequently or increasing the amount more quickly (titration schedule)
With the rise of incretin therapies, two names have emerged as leaders: tirzepatide and semaglutide
Focusing on providing the 'raw materials' (cysteine, glycine) and cofactors (B vitamins, selenium) is the most effective and sustainable strategy for supporting endogenous production